Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update. (Q37621271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

C Chaves

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

C R Marque

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J P Machado de Sousa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A W Zuardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J A S Crippa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S M Dursun

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J E Hallak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

Brazilian Journal of Medical and Biological Research

11 February 2020

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1002-1014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19855900%20AND%20SRC:MED&resulttype=core&format=json

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Serine racemase is predominantly localized in neurons in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

D-alanine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Neuroprotection by tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Maintained improvement with minocycline of a patient with advanced Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Possible antipsychotic effects of minocycline in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Effects of D-cycloserine on negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Minocycline as adjunctive therapy for schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Glycine transport inhibitors and the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

N-methyl-D-aspartate receptor subtype mediated bidirectional control of p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Bringing order to the glutamate chaos in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

Schizophrenia: the fundamental questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009001100002